Biosimilars are highly similar to the reference product notwithstanding minor differences in clinically inactive components. There are no clinically meaningful differences between the
Register now for your free, tailored, daily legal newsfeed service.
Find out more about Lexology or get in touch by visiting our About page.
RegisterBiosimilars - IP Strategy and Commercialization Aspects
To view this article you need a PDF viewer such as Adobe Reader.
If you can't read this PDF, you can view its text here.
Popular articles from this firm
